Proteasome inhibitors as potential novel anticancer agents

Drug Resistance Updates

Volumn 2, Issue 4, 1999, Pages 215-223

  Dou, Q Ping ^a   Li, Benyi ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 0033178142     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0095     Document Type: Article

References (90)

1. Bos J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
2. Sherr C. J. Cancer cell cycles. Science. 274:1996;1672-1677.
3. Spencer C. A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 56:1991;1-48.
4. Hollstein M., Sidransky D., Vogelstein B. p53 mutations in human cancers. Science. 253:1991;49-53.
5. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
6. Mes-Masson A. M., McLaughlin J., Daley G. Q. Overlapping cDNA clones define the complete coding region for the p210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A. 83:1986;9768-9772.
7. Bedi A., Griffin C. A., Barber J. P. Growth factor-mediated terminal differentiation of chronic myeloid leukemia. Cancer Res. 54:1994;5535-5538.
8. Nishii K., Kabarowski J. H., Gibbons D. L. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene. 13:1996;2225-2234.
9. Reed J. C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
10. Rampino N., Yamamoto H., Ionov Y., Li Y. Somatic frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype. Science. 275:1997;967-969.
11. Meijerink J. P., Mensink E. J., Wang K. Hematopoietic malignancies demonstrate loss-of-function mutations of Bax. Blood. 91:1998;2991-2997.
12. Molica S., Dattilo A., Giulino C. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica. 83:1998;1122-1124.
13. Krajewski S., Blomqvist C., Franssila K. Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
14. Tai Y. T., Lee S., Niloff E. Bax protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 16:1998;2583-2590.
15. Harima Y., Harima K., Shikata N. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol. 124:1998;503-510.
16. McPake C. R., Tillman D. M., Poquette C. A. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. Oncol Res. 10:1998;235-244.
17. Miyashita T., Reed J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
18. Milner J. DNA Damage, p53 and anticancer therapies. Nat Med. 1:1995;879-880.
19. Tamiya S., Etoh K., Suzushima H. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 91:1998;3935-3942.
20. Beltinger C., Kurz E., Bohler T. CD95 (APO-1/Fas) mutations in childhood T- lineage acute lymphoblastic leukemia. Blood. 91:1998;3943-3951.
21. Lee S. H., Shin M. S., Park W. S. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 59:1999;3068-3072.
22. Lee S. H., Shin M. S., Park W. S. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 18:1999;3754-3760.
23. Lee S., Christakos S., Small M. B. Apoptosis and signal transduction: clues to a molecular mechanism. Curr Opin Cell Biol. 5:1993;286-2891.
24. Dou Q. P., An B., Will P. L. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci U S A. 92:1995;9019-9023.
25. Linette G. P., Li Y., Roth K. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A. 93:1996;9545-9552.
26. Dou Q. P. Putative roles of retinoblastoma protein in apoptosis. Apoptosis. 2:1997;5-8.
27. Kinoshita T., Yokota T., Arai K. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene. 10:1995;2207-2212.
28. Grassilli E., Salomoni P., Perrotti D. Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction. Cancer Res. 59:1999;2451-2456.
29. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol. 7:1995;215-223.
30. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 79:1994;13-21.
31. Lewin B. Driving the cell cycle: M phase kinase, its partners, and substrates. Cell. 61:1990;743-752.
32. Glotzer M., Murray A. W., Kirschner M. W. Cyclin is degraded by the ubiquitin pathway. Nature. 349:1991;132-138.
33. Koff A., Giordano A., Desai D. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 257:1992;1689-1694.
34. Dou Q. P., Levin A. H., Zhao S. Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res. 53:1993;1493-1497.
35. Won K. A., Reed S. I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 15:1996;4182-4193.
36. WAFI/CIPIexpression. Biochem Biophys Res Commun. 227:1996;564-569.
37. Pagano M., Tam S. W., Theodoras A. M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
38. Maki C. G., Huibregtse J. M., Howley P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:1996;2649-2654.
39. Boyer S. N., Wazer D. E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624.
40. Hofmann F., Martelli F., Livingston D. M. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10:1996;2949-2459.
41. Hateboer G., Kerkhoven R. M. Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 10:1996;2960-2970.
42. Grimm L. M., Goldberg A. L., Poirier G. G. Proteasomes play an essential role in thymocyte apoptosis. EMBO J. 15:1996;3835-3844.
43. Sadoul R., Fernandez P. A., Quiquerez A. L. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 15:1996;3845-3852.
44. Imajoh-Ohmi S., Kawaguchi T., Sugiyama S. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 217:1995;1070-1077.
45. Omura S., Matsuzaki K., Fujimoto T. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J Antibiot (Tokyo). 44:1991;117-118.
46. Fenteany G., Standaert R. F., Lane W. S. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995;268; 726-731.
47. Fujita E., Mukasa T., Tsukahara T. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors. Biochem Biophys Res Commun. 224:1996;74-79.
48. Shinohara K., Tomioka M., Nakano H. Apoptosis induction resulting from proteasome inhibition. Biochem J. 317:1996;385-388.
49. Lopes U. G., Erhardt P., Yao R. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 272:1997;12893-12896.
50. Tanimoto Y., Onishi Y., Hashimoto S. Peptidyl aldehyde inhibitors of proteasome induce apoptosis rapidly in mouse lymphoma RVC cells. J Biochem (Tokyo). 121:1997;542-549.
51. Drexler H. C. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A. 94:1997;855-860.
52. An B., Goldfarb R. H., Siman R. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5:1998;1062-1075.
53. Green D. R., Reed J. C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
54. Li, B. Dou, Q. P. Proteasome inhibitors overcome Bcl-2- and Bcr-Abl-mediated protection through accumulating Bax and subsequently inducing cytochrome c-dependent apoptosis. Submitted.
55. Chang Y. C., Lee Y. S., Tejima T. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9:1998;79-84.
56. White E. Regulation of apoptosis by the transforming genes of the DNA tumor virus adenovirus. Proc Soc Exp Biol Med. 204:1993;30-39.
57. Harrington E. A., Bennett M. R., Fanidi A. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
58. Fearnhead H. O., Rodriguez J., Govek E. E. Oncogene-dependent apoptosis is mediated by caspase-9. Proc Natl Acad Sci U S A. 95:1998;13664-13669.
59. Orlowski R. Z., Eswara J. R., Lafond-Walker A. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58:1998;4342-4348.
60. Hannun Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
61. Spataro V., Toda T., Craig R. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit. J Biol Chem. 272:1997;30470-30475.
62. Orlowski R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 6:1999;303-313.
63. Reed J. C. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34:1997;S9-S19.
64. Herrmann J. L., Briones F. Jr, Brisbay S. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene. 17:1998;2889-2899.
65. Samali A., Gorman A. M., Cotter T. G. Role of Bcr-Abl kinase in resistance to apoptosis. Adv Pharmacol. 41:1997;533-552.
66. Dou Q. P., McGuire T. F., Peng Y. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther. 289:1999;781-790.
67. Okuda K., Golub T. R., Gilliland D. G. P210 Bcr/Abl, p190Bcr/Abl, and Tel/Abl activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 13:1996;1147-1152.
68. Lugo T. G., Pendergast A. M., Muller A. J. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082.
69. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 10:1994;405-455.
70. Schutze S., Wiegmann K., Machleidt T. TNF-induced activation of NF-kappa B. Immunobiology. 193:1995;193-203.
71. Wang C. Y., Mayo M. W., Korneluk R. G. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAPI and c-IAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
72. Zhou D., Brown S. A., Yu T. A high dose of ionizing radiation induces tissue-specific activation of nuclear factor-kappaB in vivo. Radiat Res. 151:1999;703-709.
73. Wu M., Lee H., Bellas R. E. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 15:1996;4682-4690.
74. Zong W. X., Edelstein L. C., Chen C. The prosurvival Bcl-2 homolog Bfl-1/Al is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev. 13:1999;382-387.
75. Grumont R. J., Rourke I. J., Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. 13:1999;400-411.
76. Wu M. X., Ao Z., Prasad K. V. IEX-IL, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science. 281:1998;998-1001.
77. Chu Z. L., McKinsey T. A., Liu L. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A. 94:1997;10057-10062.
78. Palombella V. J., Rando O. J., Goldberg A. L. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappaB. Cell. 78:1994;773-785.
79. Chen Z. J., Parent L., Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 84:1996;853-862.
80. Wang C. Y., Cusack J. C. Jr, Liu R. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 5:1999;412-417.
81. Higgins K. A., Perez J. R., Coleman T. A. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A. 90:1993;9901-9905.
82. Chomienne C., Fenaux P., Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J. 10:1996;1025-1030.
83. Grignani F., Fagioli M., Alcalay M. Acute promyelocytic leukemia: from genetics to treatment. Blood. 83:1994;10-25.
84. Yoshida H., Kitamura K., Tanaka K. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 56:1996;2945-2948.
85. Raelson J. V., Nervi C., Rosenauer A. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acidin acute promyelocytic leukemia cells. Blood. 88:1996;2826-2832.
86. Fanelli M., Minucci S., Gelmetti V. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood. 93:1999;1477-1481.
87. Chandra J., Niemer I., Gilbreath J. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 92:1998;4220-4229.
88. Delic J., Masdehors P., Omura S. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer. 77:1998;1103-1107.
89. Masdehors P., Omura S., Merle-Beral H. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol. 105:1999;752-757.
90. Adams J., Palombella V. J., Sausville E. A. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res. 59:1999;2615-2622.